Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer

Trial Details

NCT ID
NCT07407465
Phase
PHASE2
Sponsor
Gruppo Oncologico del Nord-Ovest
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Trastuzumab-Deruxtecan (T-DXd)
  • Capecitabine
  • Bevacizumab
Locations (sample)
  • Lyon, France|45.74906,4.84789
  • Marseille, France|43.29695,5.38107
  • Paris, France|48.85341,2.3488
  • Reims, France|49.26526,4.02853
  • St-Malo, France|48.64738,-2.00877

Key Eligibility Criteria

  • Written informed consent obtained from the patient/legal representative before performing any protocol-related procedures, including screening eval…
  • Patient state to comply with all the study procedures and treatments. Patients must be accessible for treatment and follow-up. Patients registered …
  • Age ≥ 18 years at the time of informed consent.
  • ECOG Performance Status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →